Satellos’ DMD treatment shows efficacy signals in adult patients

Satellos reports data from their Phase 1b study

Satellos Biosciences announced their Phase 1b results from their open-label study with SAT-3247, which aims to improve muscle regeneration in Duchenne.  SAT-3247 was safe and well-tolerated in 5 individuals with DMD that were treated for 28 days, and encouraging exploratory functional measurements were observed, prompting plans for follow-up studies.  Satellos will be presenting at CureDuchenne’s national FUTURES conference on Saturday, May 24th…

Satellos’ DMD treatment shows efficacy signals in adult patients

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.The post Satellos’ DMD treatment shows efficacy signals in adult patients appeared first on Clinical Trials Arena.